Tildrakizumab was approved in March 2018 for
Tildrakizumab was designed to block interleukin-23, a cytokine that plays an impoant role in managing the immune system and autoimmune disease. It is approved for the treatment of moderate-to-severe plaque psoriasis.Ref:
Psoriasis
HIV
Rheumatoid ahritis
Hepatitis C
Chemotherapy